MJP Associates’s Gilead Sciences GILD Stock Holding History

MJP Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$402K	Buy	2,886 +225	+8%	+$31.5K	0.05%	134
2025 Q4	$327K	Buy	2,661 +532	+25%	+$64.7K	0.04%	183
2025 Q3	$236K	Buy	2,129 +276	+15%	+$31.4K	0.03%	221
2025 Q2	$205K	Buy	+1,853	New	+$197K	0.03%	222
2023 Q3	–	Sell	-6,023	Closed	-$464K	–	178
2023 Q2	$464K	Sell	6,023 -967	-14%	-$77.1K	0.15%	76
2023 Q1	$580K	Buy	6,990 +412	+6%	+$34.1K	0.18%	61
2022 Q4	$565K	Buy	6,578 +865	+15%	+$68.5K	0.16%	68
2022 Q3	$352K	Buy	5,713 +783	+16%	+$49.4K	0.11%	84
2022 Q2	$305K	Buy	+4,930	New	+$305K	0.09%	97

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MJP Associates's GILD Position: Q1 2026 in Review

MJP Associates increased its Gilead Sciences (GILD) stake by 8.5% in Q1 2026, buying an estimated $31.5K and bringing the position to 2,886 shares worth $402K. The position accounts for 0.05% of the portfolio, ranked #134.

MJP Associates first reported a position in GILD in Q2 2022 and has held it in 9 quarters since. The position peaked at $580K in Q1 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

MJP Associates held 2,886 shares of Gilead Sciences worth $402K as of Q1 2026.
MJP Associates bought 225 Gilead Sciences shares in Q1 2026, an estimated $31.5K.
Gilead Sciences made up 0.05% of MJP Associates's portfolio in Q1 2026, its #134 holding.
MJP Associates first reported a position in Gilead Sciences in Q2 2022 and has held it in 9 quarters since.
MJP Associates's Gilead Sciences position peaked at $580K in Q1 2023.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.